What is the most likely diagnosis and recommended management for a patient with atypical left‑shifted myeloid maturation and 6.9% CD34‑positive myeloblasts?

Diagnosis and Management of High-Grade Myeloid Neoplasm with 6.9% CD34+ Myeloblasts

This patient most likely has myelodysplastic syndrome (MDS) with excess blasts, and requires immediate risk stratification using IPSS-R scoring followed by treatment with hypomethylating agents (azacitidine) or consideration for allogeneic stem cell transplantation based on age, fitness, and donor availability.

Diagnostic Classification

The finding of 6.9% CD34+ myeloblasts with atypical left-shifted myeloid maturation is consistent with MDS with excess blasts (MDS-EB). According to current classification systems, this blast percentage (5-10%) places the patient in the MDS-EB-1 category 1. The presence of CD34+ blasts with immunophenotypic abnormalities and left-shifted maturation is characteristic of MDS, where CD34 expression on myeloid precursors is typically associated with more aggressive disease 2, 3.

Critical Diagnostic Considerations

• Rule out AML with recurrent genetic abnormalities: The unusual immunophenotype warrants molecular testing for NPM1 mutation, KMT2A rearrangement, and NPM1::MLF1 fusion, as these can present with oligoblastic features that mimic MDS 4
• Exclude TP53-mutated disease: Multihit TP53 mutations can present with atypical blast morphology and may rapidly evolve to pure erythroid leukemia 4
• Verify blast percentage: The 6.9% CD34+ cells represents the immunophenotypically aberrant population; morphologic blast count should be confirmed as this determines classification

Mandatory Risk Stratification

IPSS-R scoring must be calculated immediately 1. This requires:

• Cytogenetic analysis (most critical prognostic factor)
• Complete blood count with differential
• Bone marrow blast percentage (morphologic confirmation)
• Hemoglobin, platelet count, and absolute neutrophil count

The IPSS-R score determines whether this is lower-risk (very low, low, intermediate) or higher-risk (high, very high) disease, which fundamentally changes management 1.

Treatment Algorithm

For Higher-Risk MDS (IPSS-R High or Very High)

Fit patients ≤70 years with a donor:

• Proceed to allogeneic stem cell transplantation (allo-SCT) as definitive therapy 1
• May use 2-6 cycles of azacitidine as bridge therapy to reduce blast burden or for logistical reasons while arranging transplant 1

Patients >70 years or younger without a donor:

• Azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days 1
• Minimum 6 cycles required before assessing response, as most patients only respond after several courses 1
• Alternative "5-2-2" regimen is acceptable for practical reasons 1

Very frail patients:

• Supportive care with RBC transfusions and antibiotics 1

For Intermediate-Risk MDS (IPSS-R Intermediate)

Treatment decision depends on:

• Age and comorbidities
• Severity of cytopenias
• Presence of high-risk somatic mutations (TP53, ASXL1, RUNX1)
• Response to initial therapy

May be treated as either lower-risk or higher-risk MDS based on these factors 1.

Prognostic Implications of CD34+ Blasts

The presence of elevated CD34+ myeloblasts (6.9%) carries significant prognostic weight:

• Elevated CD34+ cells correlate with shorter overall survival and higher leukemic transformation rates 2
• Myeloid antigen ratio (HLA-DR/CD11b) is typically elevated in MDS and predicts worse outcomes 2
• Persistent immunophenotypic aberrancies after hypomethylating therapy occur in 85% of patients, indicating difficulty in eradicating the neoplastic clone 5
• Patients achieving immunophenotypic improvement have superior progression-free survival 5

Critical Pitfalls to Avoid

1. Do not delay molecular testing: NPM1 mutations and other recurrent genetic abnormalities can present with <10% blasts but should be classified as AML, fundamentally changing treatment 4

2. Do not stop azacitidine prematurely: Response assessment should occur after at least 6 cycles, not earlier 1

3. Do not assume CD34 negativity rules out high-grade disease: Approximately 4% of myeloid neoplasms have unusual blast phenotypes (CD34-negative or minimal) that may represent NPM1-mutated AML or TP53-mutated disease 4

4. Do not overlook transplant candidacy: For fit patients with higher-risk disease, allo-SCT remains the only potentially curative option and should be evaluated early 1

Monitoring During Treatment

• Flow cytometry immunophenotyping should be repeated to assess for reduction in aberrant CD34+ myeloid progenitors 5
• Cytogenetic response should be monitored in patients with baseline abnormalities 1
• Hematologic improvement in one or more lineages (erythroid, platelet, neutrophil) is associated with survival prolongation 1